Science news

<<  return


Evolocumab Scores in Long-Awaited FOURIER Outcomes Trial: Top-line Results

Additional LDL-cholesterol lowering with the proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor evolocumab (Repatha, Amgen) significantly reduced the risk of cardiovascular events in patients with atherosclerotic CV disease, according to newly released top-line results.

The long-awaited FOURIER Outcomes trial met its primary end point—a composite of CV death, MI, stroke, and hospitalization for unstable angina or coronary revascularization—and a key secondary end point—a composite of CV death, MI, or stroke. And, according to the company, no new safety signals were observed.